• Publications
  • Influence
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
  • 590
  • 26
A DNA damage checkpoint in Caulobacter crescentus inhibits cell division through a direct interaction with FtsW.
Following DNA damage, cells typically delay cell cycle progression and inhibit cell division until their chromosomes have been repaired. The bacterial checkpoint systems responsible for these DNAExpand
  • 96
  • 10
  • Open Access
T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
BACKGROUND Immune checkpoint inhibitors provide significant clinical benefit to a subset of patients, but novel prognostic markers are needed to predict which patients will respond. This study wasExpand
  • 62
  • 4
  • Open Access
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Tumor neoantigens arising from somatic mutations in the cancer genome are less likely to be subject to central immune tolerance and are therefore attractive targets for vaccine immunotherapy. WeExpand
  • 34
  • 2
  • Open Access
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.
BACKGROUND PD-L1 expression and tumor mutational burden (TMB) have emerged as important biomarkers of response to immune checkpoint inhibitor (ICI) therapy. These biomarkers have each succeeded andExpand
  • 46
  • 2
  • Open Access
Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs
The HDAC inhibitor, entiniostat, impairs myeloid immunosuppressive function, and in combination with immune checkpoint inhibitors, improves T-cell responses in models of breast and pancreaticExpand
  • 27
  • 2
Relationship between lymphopenia and objective response rate with programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis.
e14512Background: Lymphopenia is frequent in advanced cancers, but the impact of absolute lymphocyte count (ALC) on clinical responses with PD-1 immune checkpoint inhibitors is unknown. Methods: WeExpand
  • 2
Differential variation analysis enables detection of tumor heterogeneity using single-cell RNA-sequencing data.
Tumor heterogeneity provides a complex challenge to cancer treatment and is a critical component of therapeutic response, disease recurrence, and patient survival. Single-cell RNA-sequencingExpand
  • 4
Pancreatic cancer: Next-generation algorithms for neoantigen selection
Predicting clinical outcomes in cancer using neoantigen burden is imperfect because current algorithms use only the binding affinity of putative neoantigens to HLA. A new study models pancreaticExpand
  • 1
Relationship of lymphocyte and eosinophil counts and immune-related adverse events in recipients of programmed death-1 (PD-1) inhibitor therapy: A single-center retrospective analysis.
e14586Background: Inhibition of the PD-1 checkpoint can cause immune activation in non-target tissues, resulting in immune-related adverse events (irAE) in up to 50% of patients. Biomarkers that areExpand
  • 1